Loading clinical trials...
Loading clinical trials...
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Conditions
Interventions
EDP-305 1 mg
EDP-305 2.5 mg
+1 more
Locations
86
United States
Digestive Health Specialists of the Southeast
Dothan, Alabama, United States
Arkansas Diagnostic Center
Little Rock, Arkansas, United States
Texas Clinical Research Institute
Little Rock, Arkansas, United States
Southern California Research Center
Coronado, California, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
California Liver Research Institue
Pasadena, California, United States
Start Date
December 27, 2017
Primary Completion Date
December 19, 2019
Completion Date
January 16, 2020
Last Updated
May 18, 2021
NCT07304843
NCT07449793
NCT05749822
NCT05751967
NCT06755541
NCT07296458
Lead Sponsor
Enanta Pharmaceuticals, Inc
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions